A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial

Am Heart J. 2018 Oct:204:190-195. doi: 10.1016/j.ahj.2018.07.002. Epub 2018 Jul 10.

Abstract

Mineralocorticoid receptor antagonists (MRAs) decrease morbidity and mortality in patients with heart failure (HF). However, spironolactone, a non-selective MRA, has been shown to exert a harmful effect on glucose homeostasis. The objective of this multicenter, randomized, controlled, double-blind trial was to compare the effects of spironolactone to those of the selective MRA eplerenone on glucose homeostasis among 62 HF patients with glucose intolerance or type II diabetes. Trial registration number:NCT01586442.

Publication types

  • Comparative Study
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood
  • Biomarkers / urine
  • Blood Glucose / metabolism*
  • Diabetes Mellitus, Type 2 / complications*
  • Double-Blind Method
  • Eplerenone / adverse effects
  • Eplerenone / therapeutic use*
  • Female
  • Glucose Intolerance / complications*
  • Glycated Hemoglobin / metabolism
  • Heart Failure / blood*
  • Heart Failure / complications
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Homeostasis*
  • Humans
  • Insulin / blood
  • Insulin Resistance
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / adverse effects
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Prospective Studies
  • Spironolactone / adverse effects
  • Spironolactone / therapeutic use*
  • Stroke Volume

Substances

  • Biomarkers
  • Blood Glucose
  • Glycated Hemoglobin A
  • Insulin
  • Mineralocorticoid Receptor Antagonists
  • hemoglobin A1c protein, human
  • Spironolactone
  • Eplerenone

Associated data

  • ClinicalTrials.gov/NCT01586442